Octopus leads £2 million investment round into TrialReach

Octopus leads £2 million investment round into TrialReach

Octopus has led a £2 million investment round into TrialReach, an online platform that is transforming clinical trials by connecting patients with healthcare companies and research organisations to make new treatments available more quickly and efficiently. Octopus is investing alongside existing investors Amadeus Capital Partners, which first invested in TrialReach in 2011.

Founded in 2010, TrialReach has successfully developed its ground-breaking platform and already helped thousands of patients access new treatments worldwide.

TrialReach's platform provides details of over 70,000 clinical trials that are currently authorised and regulated by health authorities. Information on each clinical trial is provided in a clear and simple way to enable patients and their families to explore and compare all available options and make informed decisions.

Alliott Cole, a Principal on the Ventures team at Octopus, said: "We are really excited to be partnering TrialReach at this stage of its development. The team has created a unique platform that has the ability to improve the efficiency of medical research, by making it easier for people to explore, understand and access the latest clinical trials. Data shows that finding the required number of patients delays the vast majority of clinical trialsTrialReach offers a fantastic solution to a problem that the pharmaceutical industry is only going to find more challenging as it looks to recruit patients for clinical trials to support drug development.

"We look forward to working with the team as they develop the business to address what is a global market opportunity."

Working closely with clinical trial organisations, TrialReach's unique approach combines proprietary search technology, new and exclusive content and communication channels between patients and physicians to make clinical trials easy to find, easy to understand and easy to access.

Commenting on the successful fundraising, Pablo Graiver, CEO of TrialReach, said: "It's a huge endorsement of our technology and vision to secure this investment from Octopus and we are delighted to have them on board, alongside the continuing support of Amadeus.  Together, Octopus and Amadeus bring valuable experience of growing technology companies combined with sector knowledge to help us achieve our ambitious business goals. The funding will help us develop our products further and launch new solutions that we have in the pipeline, all with the consistent view of helping patients and medical organisations make clinical research more efficient. The industry is crying out for innovation and effective solutions to support a growing research market.

"We are especially pleased that we have managed to secure this investment at a time when funding is hard to obtain and reserved only for the best technology companies. The work now really starts, as we look to radically improve information, access and efficiencies in the clinical trials industry, worldwide."

For further information, please contact:

Georgina Turner, PR, Octopus                                                                    Rachel Turner, PR, TrialReach

0207 776 7968                                                                                                    07985 805805

[email protected]                                                         [email protected]

About the ventures team at Octopus Investments

The ventures team at Octopus are straight talking human investors that back talented people rather than specific sectors. We focus on identifying fast growth businesses which can scale explosively to create, transform or dominate an industry.  We can invest from £250,000 to £5 million and prefer to partner teams based in the UK.

The work of our ventures team is supported by access to the Octopus Venture Partners, a network of approximately 100 outstanding business leaders, entrepreneurs and private investors providing an invaluable wealth of expertise and resource for our portfolio companies, as well as investing on a deal-by-deal basis alongside Octopus venture funds. This blend of knowledge and skill has allowed us to help many great companies across several sectors thrive in recent years including Zoopla; Graze.com; SwiftKey; and, Secret Escapes.

About Octopus Investments

Founded in 2000, Octopus is one of the UK's fastest growing investment management companies. We currently manage £3 billion assets on behalf of 50,000 customers. We offer a straight-talking approach to investments, exceptional customer service and a range of products that do what they say they will.

Working closely with over 3,000 financial advisers and wealth managers, often via strategic partnerships, we provide tax efficient investment solutions and discretionary fund management services to retail investors. Our core products include a range of venture capital trusts, enterprise investment schemes, inheritance tax services and a discretionary fund management solution.

We focus on areas of the market that are inefficient and where we believe hard work pays off for our customers. Our four areas of investment expertise are: ventures; specialist finance; smaller companies; and multi manager. We have dominant or high-growth positions in all of these markets, and invest into some of the UK's most dynamic smaller companies, providing a wide range of funding options for exceptional businesses.

Over the last decade, Octopus has won a number of awards for its customer-driven product design and services. We've twice been voted one of the best 100 SMEs to work for, we're one of only two investment firms to have ever been rated AAA for service by Citywire, and in November 2012 we were awarded the Financial Adviser 5 Star Award for quality service from investment product providers.

For more information visit www.octopusinvestments.com

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.